摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-羟基-[1,1-联苯]-4-羧酸甲酯 | 40501-41-5

中文名称
4-羟基-[1,1-联苯]-4-羧酸甲酯
中文别名
4'-羟基-4-联苯基羧酸甲酯
英文名称
methyl 4'-hydroxy-4-biphenylcarboxylate
英文别名
4'-hydroxy-biphenyl-4-carboxylic acid methyl ester;methyl 4′-hydroxy-[1,1′-biphenyl]-4-carboxylate;methyl 4’-hydroxy-4-biphenylcarboxylate;Methyl 4'-hydroxy[1,1'-biphenyl]-4-carboxylate;methyl 4-(4-hydroxyphenyl)benzoate
4-羟基-[1,1-联苯]-4-羧酸甲酯化学式
CAS
40501-41-5
化学式
C14H12O3
mdl
——
分子量
228.247
InChiKey
PHBQSOODLMGROT-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    227-228 °C(Solv: acetone (67-64-1))
  • 沸点:
    380.2±25.0 °C(Predicted)
  • 密度:
    1.194±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    3.6
  • 重原子数:
    17
  • 可旋转键数:
    3
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.07
  • 拓扑面积:
    46.5
  • 氢给体数:
    1
  • 氢受体数:
    3

安全信息

  • 海关编码:
    2922299090
  • 危险性防范说明:
    P261,P280,P301+P312,P302+P352,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H335
  • 储存条件:
    室温下,使用了惰性气体。

SDS

SDS:93ed5c6f59227a392dd0fff12e9e98a0
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 4-(4-Methoxycarbonylphenyl)phenol
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 4-(4-Methoxycarbonylphenyl)phenol
CAS number: 40501-41-5

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C14H12O3
Molecular weight: 228.2

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量
    • 1
    • 2
    • 3
    • 4
    • 5

反应信息

点击查看最新优质反应信息

文献信息

  • Synthesis and polymerization reactions of cyclic imino ethers. VI. Polymers with biphenyl structure
    作者:Jozef Lustoň、Juraj Kronek、Angela Kleinová、Ivica Janigová、Helena Valentová、Jan Nedbal
    DOI:10.1002/pola.26199
    日期:2012.10.1
    AA+BB‐type polyaddition reactions with aliphatic dicarboxylic acids. Both types of polymerizations have been performed in melt and in solution. The structures of the polymers were determined, and the thermal properties of the polymers were evaluated. Liquid‐crystalline (LC) structures of the prepared polymers were observed by DSC measurements and optical microscopy. The polyaddition reactions of the monomers
    由相应的羧酸经过酯化反应和随后的氨基醇酰胺化反应,制得了AB型单体和AA型双官能共聚单体,其中有两个2-恶唑啉环和一个联苯结构单元。通过亚硫酰氯处理,然后在水溶液中用碳酸钠释放游离碱,可将酰胺环化为2-恶唑啉结构。制备的单体用于溶液中联苯结构的相邻环上具有2-恶唑啉和酚基的AB型单体的加聚聚合反应。AA型单体用于与脂肪族二羧酸的AA + BB型加成反应。两种类型的聚合均在熔融和溶液中进行。确定了聚合物的结构,并评估了聚合物的热性能。通过DSC测量和光学显微镜观察了所制备聚合物的液晶(LC)结构。含有2-恶唑啉环和联苯单元的单体的加聚反应是制备含有聚醚酰胺和聚酯酰胺的联苯单元的一种新的有效方法。©2012 Wiley Periodicals,Inc. J Polym Sci A部分:Polym Chem,2012年 含有2-恶唑啉环和联苯单元的单体的加聚反应是制备含有聚醚酰胺和聚酯酰胺的联苯单元的一种新的有效方法。©2012
  • [EN] SUBSTITUTED PIPERIDINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE<br/>[FR] CARBAMATES DE PIPERIDINE A SUBSTITUTION UTILISES EN TANT QU'INHIBITEURS DE LA LIPASE HORMONOSENSIBLE
    申请人:NOVO NORDISK AS
    公开号:WO2004111032A1
    公开(公告)日:2004-12-23
    Novel substituted piperidine carbamates, pharmaceutical compositions comprising them and use thereof in the treatment and/or prevention of diseases and disorders related to hormone sensitive lipase. More particularly, the compounds are useful for the treatment and/or prevention of diseases and disorders in which modulation of the activity of hormone sensitive lipase is beneficial.
    新型替代哌啶羰酸酯化合物,包括它们的药物组合物以及在治疗和/或预防与激素敏感性脂肪酶相关的疾病和紊乱中的应用。更具体地说,这些化合物对于治疗和/或预防需要调节激素敏感性脂肪酶活性的疾病和紊乱是有益的。
  • 4-Biphenyl and 2-naphthyl substituted 6,7-dimethoxytetrahydroisoquinoline derivatives as potent P-gp modulators
    作者:Nicola Antonio Colabufo、Francesco Berardi、Mariangela Cantore、Maria Grazia Perrone、Marialessandra Contino、Carmela Inglese、Mauro Niso、Roberto Perrone、Amalia Azzariti、Grazia Maria Simone
    DOI:10.1016/j.bmc.2008.01.055
    日期:2008.4.1
    this series whilst the presence of hydroxy or methoxy substituents seems to be negligible. In the naphthyl series, both the basicity and the presence of H-bond donor or acceptor groups seem to be negligible. Moreover, the lipophilicity did not influence the P-gp inhibition activity of each series. Specific biological assays have been carried out to establish the P-gp interacting mechanism of tested
    从铅化合物1(EC(50)= 1.64 microM)开始,其非碱性核已在构象上受到4-联苯和2-萘基部分的限制。在每个系列中,我们研究了H键供体或受体取代基,碱度和亲脂性(clogP)的存在是否与受试化合物的P-gp抑制活性相关。在联苯系列中,衍生物4d表现出最好的结果(EC(50)= 0.05 microM)。发现相应酰胺3d的活性较低(EC(50)= 3.5 microM),确定碱性在该系列中的重要性,而羟基或甲氧基取代基的存在似乎可以忽略不计。在萘系列中,碱度和氢键供体或受体基团的存在似乎都可以忽略不计。此外,亲脂性不影响每个系列的P-gp抑制活性。已经进行了特定的生物学测定,以建立区分底物和抑制剂的被测化合物的P-gp相互作用机制。而且,化合物4d表现出有效的P-gp抑制活性,并且对BCRP泵具有良好的选择性。
  • [EN] METHOD FOR THE METAL-FREE PREPARATION OF A BIARYL BY A PHOTOSPLICING REACTION AND THEIR USES<br/>[FR] PROCÉDÉ DE PRÉPARATION SANS MÉTAL D'UN BIARYLE PAR RÉACTION DE PHOTOCOLLAGE ET UTILISATIONS ASSOCIÉES
    申请人:LEIBNIZ INST FUER NATURSTOFF FORSCHUNG UND INFEKTIONSBIOLOGIE E V HANS KNOELL INST HKI
    公开号:WO2019101679A1
    公开(公告)日:2019-05-31
    The present invention relates to a method for the metal-free preparation of a biaryl compound by a photosplicing reaction and its use in the preparation of chemical compounds, preferably of active ingredients e.g. in the fields of pharmaceuticals and agrochemicals. In particular, it refers to a method for the regiocontrolled preparation of a biaryl compound of formula (I): Ar-Ar' by photochemically reacting a precursor compound of formula (II): Ar-L-Ar' to form a biaryl compound of general formula: Ar-L-Ar' (II) → Ar-Ar' (I) wherein Ar and Ar', independently of each other, represent an unsubstituted or substituted C6-C20 aryl group or a heteroaryl group with 5–20 ring atoms selected from carbon, nitrogen, oxygen and sulfur, and L represents a group –X–Y–Z– as defined herein. The biaryl compounds are generally suitable as intermediates or key building blocks in a very broad spectrum of organic chemical syntheses and their respective utilities. Their use within the field of synthesis of active ingredients is an aspect of the invention, and their use in the preparation of pharmaceutically active ingredients is particularly preferred.
    本发明涉及一种通过光切割反应无金属制备联芳烃化合物的方法,以及其在化学化合物制备中的用途,特别是在制药和农药领域中的活性成分的制备中的用途。具体而言,它涉及一种通过光化学反应化学前体化合物(II):Ar-L-Ar'与形成一般式的联芳烃化合物(II)→Ar-Ar'(I)反应,从而实现联芳烃化合物(I)的区域控制制备的方法,其中Ar和Ar'分别表示未取代或取代的C6-C20芳基或由碳、氮、氧和硫选择的5-20个环原子的杂芳基,L表示如本文所定义的一个组-X-Y-Z-。这些联芳烃化合物通常适用于有机化学合成的广泛领域中的中间体或关键构建块,以及它们各自的用途。它们在活性成分合成领域中的用途是本发明的一个方面,它们在制备药用活性成分中的用途尤为理想。
  • Synthesis and Characterization of Potent Bivalent Amyloidosis Inhibitors That Bind Prior to Transthyretin Tetramerization
    作者:Nora S. Green、Satheesh K. Palaninathan、James C. Sacchettini、Jeffery W. Kelly
    DOI:10.1021/ja030294z
    日期:2003.11.1
    The misfolding of transthyretin (TTR), including rate-limiting tetramer dissociation and partial monomer denaturation, is sufficient for TTR misassembly into amyloid and other abnormal quaternary structures associated with senile systemic amyloidosis, familial amyloid polyneuropathy, and familial amyloid cardiomyopathy. Monovalent small molecules that bind to one or both of the unoccupied thyroid hormone
    甲状腺素运载蛋白 (TTR) 的错误折叠,包括限速四聚体解离和部分单体变性,足以使 TTR 错误组装成淀粉样蛋白和其他与老年系统性淀粉样变性、家族性淀粉样多发性神经病和家族性淀粉样变心肌病相关的异常四级结构。与 TTR 四级结构界面处的一个或两个未占据的甲状腺激素结合位点结合的单价小分子稳定了天然状态,充分提高了四聚体解离的动力学障碍,从而使解离速度变慢,因此淀粉样变性变慢。本文报道了同时结合两个结合位点的二价淀粉样蛋白抑制剂。候选二价抑制剂通常不能与天然 TTR 四聚体结合,并且由于强烈的抑制剂取向偏好,通常不参与单价结合。然而,如果抑制剂在组​​装发生前拦截蛋白质,则 TTR 四级结构可以在几个二价抑制剂周围组装。以这种方式制备的一些野生型 TTR.二价抑制剂复合物在受到大量变性压力时保留了四聚体结构(8 M 尿素,120 小时)。最好的二价抑制剂将酸介导的 TTR (3.6 microM)
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐